|ORIGINAL ARTICLE |
| || || |
|Year : 2009 | Volume : 5 | Issue : 2 | Page : 107-112 |
Time trial: A prospective comparative study of the time-resource burden for three-dimensional conformal radiotherapy and intensity-modulated radiotherapy in head and neck cancers
Vedang Murthy, Tejpal Gupta, Avinash Kadam, Sarbani Ghosh-Laskar, Ashwini Budrukkar, Reenadevi Phurailatpam, Rajeshri Pai, Jaiprakash Agarwal
Department of Radiation Oncology, Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India
|Date of Web Publication ||16-Jun-2009 |
Tata Memorial Hospital and Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai - 410 210
Introduction: An ongoing institutional randomized clinical trial comparing three-dimensional conformal radiotherapy (3D CRT) and intensity-modulated radiotherapy (IMRT) provided us an opportunity to document and compare the time-manpower burden with these high-precision techniques in head and neck cancers.
Materials and Methods: A cohort of 20 consecutive patients in the ongoing trial was studied. The radiotherapy planning and delivery process was divided into well-defined steps and allocated human resource based on prevalent departmental practice. Person-hours for each step were calculated.
Results: Twelve patients underwent IMRT and eight patients had 3D CRT. The prerandomization steps (upto and including approval of contours) were common between the two arms, and expectedly, the time taken to complete each step was similar. The planning step was carried out postrandomization and the median times were similar for 3D CRT (312 min, 5.2 person-hours) and IMRT (325.6 min, 5.4 person-hours). The median treatment delivery time taken per fraction varied between the two arms, with 3D CRT taking 15.2 min (0.6 person-hours), while IMRT taking 27.8 min (0.9 person-hours) (P<0.001). The total treatment time was also significantly longer in the IMRT arm (median 27.7 versus 17.8 person-hours, P<0.001). The entire process of IMRT took 48.5 person-hours while 3D CRT took a median of 37.3 person-hours. The monitor units delivered per fraction and the actual "beam-on" time was also statistically longer with IMRT.
Conclusions: IMRT required more person-hours than 3D CRT, the main difference being in the time taken to deliver the step-and-shoot IMRT and the patient-specific quality assurance associated with IMRT.
Keywords: Intensity-modulated radiotherapy, three-dimensional conformal radiotherapy, workload, person-hours, burden, manpower
|How to cite this article: |
Murthy V, Gupta T, Kadam A, Ghosh-Laskar S, Budrukkar A, Phurailatpam R, Pai R, Agarwal J. Time trial: A prospective comparative study of the time-resource burden for three-dimensional conformal radiotherapy and intensity-modulated radiotherapy in head and neck cancers. J Can Res Ther 2009;5:107-12
|How to cite this URL: |
Murthy V, Gupta T, Kadam A, Ghosh-Laskar S, Budrukkar A, Phurailatpam R, Pai R, Agarwal J. Time trial: A prospective comparative study of the time-resource burden for three-dimensional conformal radiotherapy and intensity-modulated radiotherapy in head and neck cancers. J Can Res Ther [serial online] 2009 [cited 2014 Feb 28];5:107-12. Available from: http://www.cancerjournal.net/text.asp?2009/5/2/107/52800
| > Introduction || || |
Head and neck squamous cell carcinoma (HNSCC) is ideally suited for treatment with intensity-modulated radiation therapy (IMRT) due to the presence of complex target volumes in close proximity to critical structures and the proven need for high doses of radiation for long-term control. Several studies on IMRT in HNSCC have shown impressive outcomes in terms of improved locoregional control, decreased acute toxicity, and better quality of life (QOL), though long-term results are still awaited. ,,,, Despite several potential advantages, this revolutionary new technology is not readily available in many centers, even in the developed world  due to economical, technical, and logistical factors, such as the need to procure additional software and hardware, human resource issues, and time-burden implications on a busy clinical department.
A suitable alternative to inverse planning typically associated with IMRT could be the use of forward planning with three-dimensional conformal radiotherapy (3D CRT) to produce dose distributions superior to conventional two-dimensional (2D) treatment. , While concerns have been raised regarding the resource implications with the use of IMRT at various sites, only a handful of studies have addressed this issue by measuring the additional time burden imposed by its introduction in clinical practice. ,,, No study has previously directly compared each step involved in the treatment planning and delivery process of 3D CRT and IMRT in HNSCC.
A prospective randomized trial comparing 3D CRT and IMRT in moderately advanced HNSCC with appropriate clinical endpoints is currently ongoing at our institution. Clinical and dosimetric results of this trial are still awaited, and will be reported in due course. This trial provided us with an opportunity to prospectively document and compare the time-manpower resource burden involved with the use of these high-precision radiotherapeutic techniques in head and neck cancers.
| > Materials and Methods || || |
The study population consisted of a cohort of 20 consecutive patients randomized into one of the two treatment arms of an ongoing trial comparing forward planned 3D CRT with inverse planned IMRT in moderately advanced HNSCC between May and November 2007. These 20 patients were accrued during the mid-course of the primary trial reducing the influence of the learning curve associated with such high-precision and resource-intensive techniques. The inclusion criteria for the primary trial was previously untreated, histologically proven squamous cell carcinoma of the oropharynx, hypopharynx or larynx staged as T1-T3 (excluding T1 vocal cord) and N0-2b with no distant metastases planned for radical intent treatment with definitive radiotherapy with or without concurrent systemic chemotherapy as per the prespecified protocol.
For the purpose of this study for assessing the time burden, the entire planning and delivery process was divided into specific steps [Table 1]. Each step is a well-defined entity, and was allocated human resource based on prevalent departmental practice to aid in the estimation of time and human resource requirement. A time sheet was maintained during the entire process of planning, verification, and delivery. To objectively describe the time-person burden required for the process, person-hours for each step were calculated as follows:
All patients were immobilized in a supine position using a four clamp thermoplastic mask, an appropriate neck rest, and shoulder traction. Three staff members [one radiation oncologist (RO), two radiotherapy technologists (RTTs)] were involved in the process. Fiducials were placed after patient alignment, and the patient was moved to the CT scanner for the planning CT scan.
Planning CT scan
Planning CT scan was done with the patient immobilized on a flat couch of a four-slice CT scanner (SomaTom, Siemens Medical System, Concord, CA, USA). High-resolution axial images were acquired from the vertex to 5 cm below the clavicles using 3 mm slice thickness and 100 ml intravenous contrast for better delineation. The planning CT data set was transferred to the contouring work station via network (Lantis, Siemens Medical Systems). Three staff members (one RO, one RTT, one nurse) were involved in the planning CT scan process.
Target volumes and organs-at-risk (OARs) were defined based on ICRU 50 recommendations. In brief, the gross tumor volume (GTV) encompassed all the visible and palpable primary and nodal diseases. A 5- to 10-mm 3D margin was generated and suitably modified for defining the clinical target volume (CTV). A further 5-mm margin was applied to the CTV to obtain the planning target volume (PTV). Comprehensive elective nodal irradiation was undertaken by defining the high-risk and low-risk volumes in the neck depending on the tumor characteristics and patterns of regional nodal metastasis. This step was carried out by one RO, usually a trainee. Since contouring was an integral part of the training of the junior oncologists, and they were at various levels of competency in following the consensus head and neck contouring guidelines,  this process often took longer for some patients.
The initial contours were reviewed, modified, and finally approved by a senior RO before the planning began. The final approved contours for the targets and the OARs were transferred to the planning system via the network. Until this point, the work flow and steps were common for both the arms of the trial. This was done to minimize the observer bias while contouring.
Treatment planning for 3D CRT as well as IMRT was carried out on Sunrise-Plato TPS (version 2.7.4, Nucletron BV, Veenenedaal, The Netherlands). Plato planning system has been configured for photons from a dual-energy linear accelerator (Siemens Primus, Siemens Medical Systems) equipped with 29 pairs of multileaf collimators (MLCs) for forward as well as inverse planning.
Treatment planning was done by one of the two physicists and included preplanning steps like importing and validation of image and structure data sets. 3D CRT plans were generated using 6-MV photons with seven to nine coplanar beams with MLC shaping based on the beam's eye view (BEV) projection of the target as well as OARs. Wedges were used as and when required. Beams were weighted appropriately to reduce hot or cold spots. Anterior compensative field was used at the discretion of the planner. It was a forward planning iterative process with differential wedges, weightage, and compensative fields to achieve the desired dose distribution. The prescription for phase I of 3D CRT plan was 60 Gy in 30 fractions. A sequential phase II boost plan for gross disease (10 Gy in five fractions) was also required for 3D CRT. The final treatment plan was a composite sum of both these plans.
IMRT planning was done using 6-MV photons with seven to nine equispaced coplanar beams with five to seven intensity levels. The inverse planning module of Plato uses a gradient-search algorithm for optimization. Unlike 3D CRT, which was planned in two phases as a sequential boost, IMRT was a single-phase plan using the simultaneous integrated boost (SIB) technique. The gross disease with margins was planned with a higher dose per fraction (220 cGy/fraction) for 30 fractions for a total dose of 66 Gy in 30 fractions, whereas the high-risk and low-risk elective volumes were treated with a lower dose per fraction (200 and 180 cGy/fraction, respectively) for 30 fractions. Radiobiologically, both the 3D CRT and IMRT doses that were employed were deemed equivalent.
The planning for each patient was reviewed, evaluated, modified if necessary, and approved by a senior RO along with the physicist. Two 10 × 10 cm, orthogonally acquired (at 0 and 90°), digitally reconstructed radiographs (DRRs) of the final clinically accepted plan were transferred to the simulator (Simulix HQ, Nucletron BV) via the Lantis network.
Once the plan was approved, its implementation was done on Simulix HQ by one oncologist and one technologist. This was undertaken to localize the isocenter with respect to the fiducials based on the final plan. Patients in the 3D CRT arm were planned in two phases, so they had an additional step of plan implementation before phase II of treatment began.
For all patients planned for IMRT, a quality assurance (QA) procedure was prespecified. This step was carried out by two staff members (one physicist and one RTT) and was not required in the 3D CRT arm.
Absolute output measurement of the machine was done using 0.6-cc cylindrical ion chamber at a 5-cm depth with a field size of 10 × 10 cm 2 . The IMRT plan was then transferred to a virtual water phantom with the isocenter set at the center of the effective volume of the ion chamber, placed at a depth of 5 cm. Profiles were generated for each beam and points defined off-axis in the plateau region, away from any sharp dose gradients. Doses at these points were also noted from the planning system. Measured doses and calculated doses were compared and confirmed with film dosimetry.
Set-up verification and treatment delivery
Treatment was carried out on Siemens Primus linear accelerator at a dose rate of 300 MU/min. Delivery of IMRT is facilitated by using the auto-field sequencing mode. The machine is also equipped with BeamView (version 2.2, Siemens Medical Systems), a camera-based electronic portal imaging device (EPID) for set-up verification. The set-up, verification, and actual treatment delivery were carried out by two RTTs. The time was calculated between the patient entering and exiting the treatment room (room-in to room-out). This included time for patient to change, set-up time, EPID time (once weekly), and the actual treatment (radiation beam on) time. All patients underwent online portal imaging at the first fraction and weekly thereafter with corrections made as and when necessary. This was done by an oncologist. The time taken for EPID was included in the treatment time.
| > Results || || |
Twenty patients were included in the study. Patient demographics are shown in [Table 2]. There were 12 patients who had IMRT, and 8 patients had 3D CRT. [Table 3] shows the median time taken to undertake each defined step with the two techniques.
The prerandomization steps (up to and including contouring approval) were similar between the two arms and expectedly the time taken to complete each step was no different. The contouring step had a wide range in both the arms due to the involvement of the junior trainees with varying level of experience. The planning step was carried out postrandomization, and the median time taken for producing a 3D CRT plan was 312 min (5.2 person-hours), while the IMRT plan took a median of 325.6 min (5.4 person-hours). This difference was not statistically significant.
The time taken for the daily treatment varied between the two arms, with 3DCRT taking a median of 15.2 min (0.6 person-hours) for each fraction while IMRT taking longer at a median of 27.8 min (0.9 person-hours). This difference (and the difference in person-hours) was statistically significant. The total treatment time was also significantly longer in the IMRT arm (median 27.7 versus 17.8 person-hours, P <0.001). QA was an additional step taken in patients undergoing IMRT only, and the process took an additional median time of 99.4 min (3.4 person-hours). The entire process of IMRT took 1791 min (48.5 person-hours) and was significantly longer than the process of 3D CRT which took a median of 1496.5 minutes (37.3 person-hours). The monitor units delivered per fraction and the actual "beam-on" time was also statistically different for the two arms.
| > Discussion || || |
While the comparative dosimetric and clinical outcomes with these techniques will be evaluated and reported once the trial concludes in due course, this randomized trial provided us with an opportunity to prospectively estimate and document the time and human resource burden required by a department while undertaking resource-intensive procedures such as 3D CRT and IMRT in HNSCC. This study showed that the time required for the process of IMRT is significantly longer than that for 3D CRT in HNSCC with the main difference being in the duration of treatment delivery and the extra procedure of patient-specific QA with IMRT.
There is an anticipated benefit with high-precision techniques in HNSCC. While IMRT has been used, evaluated, and reported extensively, ,,,, the utility and feasibility of 3D CRT remains relatively untested in this setting. In limited resource centers, 2D treatment with conventionally simulated fields is still considered as the standard of care. Current best evidence mandates a paradigm shift from conventional 2D to volumetric-imaging-based high-precision radiotherapy. However, there is a steep learning curve associated with the introduction of IMRT in a busy clinical department. In addition, this has significant logistic, technical, financial, and human resource implications and may not be practically achievable universally.  Moreover, this technology is being aggressively promoted and marketed while open questions remain about its long-term efficacy and cost effectiveness. 
In order to circumvent some of these issues while attempting to improve the therapeutic ratio, use of 3D CRT may be considered as a suitable intermediate step, which has been largely ignored by the head and neck radiation oncology community. Although, based on the published evidence, the value of IMRT in sparing normal tissues while enabling dose escalation is unquestionable, the role of 3D CRT as a suitable alternative needs to be better defined.
The parent trial design mandated that randomization should be done after the approval of volume delineation. This not only reduced the potential bias during the contouring process but also maintained consistency in volume delineation. As a result, the time taken for the preplanning steps was very similar in the two arms. Although detailed data on the time burden for immobilization and CT simulation are not available in the literature, they are likely to be similar to our results across institutions. The time spent on volume delineation is a direct function of the experience of the clinician and is likely to be variable. This time is also likely to reduce as the learning curve is negotiated. Our results of the contouring time are similar to those from Miles et al . who reported a median contouring time of 2.3 h (range 0.7-3.5 h) for IMRT in head and neck cancers with the authors admitting a more variable time requirement for head and neck than prostate and pelvic nodal contours.  The reason for this variability though not specified is likely to be similar to what has been reported here.
We found no statistically significant difference in the time taken for the actual physics planning between 3D CRT and IMRT. Based on our experience gained while planning the treatment of the first 20 patients in the trial (prior to starting this time trial), a significantly longer planning time was expected for 3D CRT as compared to IMRT. However, this was not the case and both the techniques took similar times for planning. It is difficult to say whether this was purely due to chance or related to the learning curves associated with either of these techniques. The optimization and planning time obtained in this study are similar to those reported in the multicenter ESTRO-QUASIMODO project. 
According to our departmental guidelines and based on the trial protocol requirements, patient-specific QA was carried out as an extra step in patients receiving IMRT. This added substantially to the overall time taken per patient. Palta et al .  have indicated that the current "estimates' of the additional time necessary for patient-specific QA in an IMRT program of 40 patients per year is 200 h.
The main difference in the two treatment techniques was however the time taken for the actual treatment delivery (room-in to room-out) with 3D CRT taking a median of 15.2 min as compared to 27.8 min for IMRT ( P <0.001). When restricting the analysis to radiation beam-on time and monitor units delivered, this difference remained statistically significant. While the monitor units and consequently beam-on time were longer for IMRT, they only partially contributed to the overall increase in the daily time by 10 min with IMRT, the main reason being the time for MLC repositioning inherent to the step-and-shoot IMRT.
The IMRT treatment time in our study is longer than that reported in the Royal Marsden Hospital study (median 12 min)  and the ESTRO-QUASIMODO study (mean 19 min).  This could partly be due to the difference in the methods of time measurement (on-couch to off-couch versus room-in to room-out). It could also be influenced by the number of fields and other technical aspects of treatment delivery such as the machine output and the dynamic mode of treatment delivery. Overall, the delivery time was generally similar to that reported in the indexed medical literature for head and neck cancers. ,,,
This work was an attempt to estimate the time-human resource burden prospectively while undertaking 3D CRT and IMRT in HNSCC in a clinical trial setting. Although in a busy service setting the time for each step may be reduced, the overall time difference between the two arms is still likely to persist. Simplification of the step-and-shoot IMRT technique may help reduce the planning and treatment delivery time further.  Although undertaking patient-specific QA and defining action levels before IMRT are common in most centers, there is some debate if this procedure can be omitted particularly after gaining considerable experience with IMRT. Further reductions in the time required for these procedures is likely with standardization of procedures, increasing familiarity, and use of class solutions.
| > Acknowledgment || || |
The authors are thankful to Mrs. Sadhana Kannan for her assistance with statistical analysis and data management.
| > References || || |
|1. ||Chao KS, Deasy JO, Markman J, Haynie J, Perez CA, Purdy JA, et al . A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001;49:907-16. [PUBMED] [FULLTEXT] |
|2. ||Eisbruch A, Marsh LH, Dawson LA, Bradford CR, Teknos TN, Chepeha DB, et al . Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004;59:28-42. [PUBMED] [FULLTEXT] |
|3. ||Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM. Intensity-modulated radiation therapy for head-and-neck cancer: the UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys 2003;57:49-60. [PUBMED] [FULLTEXT] |
|4. ||Pow EH, Kwong DL, McMillan AS, Wong MC, Sham JS, Leung LH, et al . Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys 2006;66:981-91. |
|5. ||Yao M, Dornfeld KJ, Buatti JM, Skwarchuk M, Tan H, Nguyen T, et al . Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience. Int J Radiat Oncol Biol Phys 2005;63:410-21. [PUBMED] [FULLTEXT] |
|6. ||Baker CR, Hardy V. Provision of IMRT in the UK. Part 2: Current levels, planned expansion and obstacles to implementation. Journal of Radiotherapy in Practice 2003;3:181-4. |
|7. ||Sultanem K, Shu HK, Xia P, Akazawa C, Quivey JM, Verhey LJ, et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2000;48:711-722. [PUBMED] [FULLTEXT] |
|8. ||van Dieren EB, Nowak PJ, Wijers OB, van Sornsen de Koste JR, van der Est H, et al . Beam intensity modulation using tissue compensators or dynamic multileaf collimation in three-dimensional conformal radiotherapy of primary cancers of the oropharynx and larynx, including the elective neck. Int J Radiat Oncol Biol Phys 2000;47:1299-309. |
|9. ||Bijdekerke P, Verellen D, Tournel K, Vinh-Hung V, Somers F, Bieseman P, et al . TomoTherapy: implications on daily workload and scheduling patients. Radiother Oncol 2008;86:224-30. [PUBMED] [FULLTEXT] |
|10. ||Hunt MA, Zelefsky MJ, Wolden S, Chui CS, LoSasso T, Rosenzweig K, et al . Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer. Int J Radiat Oncol Biol Phys 2001;49:623-32. [PUBMED] [FULLTEXT] |
|11. ||Miles EA, Clark CH, Urbano MT, Bidmead M, Dearnaley DP, Harrington KJ, et al . The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol 2005;77:241-6. [PUBMED] [FULLTEXT] |
|12. ||Munter MW, Thilmann C, Hof H, Didinger B, Rhein B, Nill S, et al . Stereotactic intensity modulated radiation therapy and inverse treatment planning for tumors of the head and neck region: clinical implementation of the step and shoot approach and first clinical results. Radiother Oncol 2003;66:313-21. |
|13. ||Gregoire V, Levendag P, Ang KK, Bernier J, Braaksma M, Budach V, et al . CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. Radiother Oncol 2003;69:227-36. |
|14. ||Glatstein E. The return of the snake oil salesmen. Int J Radiat Oncol Biol Phys 2003;55:561-2. [PUBMED] [FULLTEXT] |
|15. ||Gillis S, De Wagter C, Bohsung J, Perrin B, Williams P, Mijnheer BJ. An inter-centre quality assurance network for IMRT verification: results of the ESTRO QUASIMODO project. Radiother Oncol 2005;76:340-53. [PUBMED] [FULLTEXT] |
|16. ||Palta JR, Liu C, Li JG. Quality assurance of intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2008;71:S108-12. [PUBMED] [FULLTEXT] |
|17. ||Ozyigit G, Chao KS. Clinical experience of head-and-neck cancer IMRT with serial tomotherapy. Med Dosim 2002;27:91-8. [PUBMED] [FULLTEXT] |
|18. ||Takamiya R, Missett B, Weinberg V, Akazawa C, Akazawa P, Zytkovicz A, et al . Simplifying intensity-modulated radiotherapy plans with fewer beam angles for the treatment of oropharyngeal carcinoma. J Appl Clin Med Phys 2007;8:26-36. [PUBMED] |
[Table 1], [Table 2], [Table 3]
|This article has been cited by |
|1 ||Hybrid adaptive radiotherapy with on-line MRI in cervix cancer IMRT || |
| ||Seungjong Oh,James Stewart,Joanne Moseley,Valerie Kelly,Karen Lim,Jason Xie,Anthony Fyles,Kristy K. Brock,Anna Lundin,Henrik Rehbinder,Michael Milosevic,David Jaffray,Young-Bin Cho |
| ||Radiotherapy and Oncology. 2013; |
| ||[Pubmed] |
|2 ||Intensity-modulated radiation therapy for head and neck cancer: Systematic review and meta-analysis || |
| ||Gustavo Nader Marta,Valter Silva,Heloisa de Andrade Carvalho,Fernando Freire de Arruda,Samir Abdallah Hanna,Rafael Gadia,João Luis Fernandes da Silva,Sebastião Francisco Miranda Correa,Carlos Eduardo Cintra Vita Abreu,Rachel Riera |
| ||Radiotherapy and Oncology. 2013; |
| ||[Pubmed] |
|3 ||The potential of helical tomotherapy in the treatment of head and neck cancer || |
| ||Van Gestel, D. and Verellen, D. and Van de Voorde, L. and Deost, B. and De Kerf, G. and Vanderveken, O. and Van Laer, C. and Van Denweyngaert, D. and Vermorken, J.B. and Gregoireg, V. |
| ||Oncologist. 2013; 18(6): 697-706 |
| ||[Pubmed] |
|4 ||RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison || |
| ||Van Gestel, D. and van Vliet-Vroegindeweij, C. and Van den Heuvel, F. and Crijns, W. and Coelmont, A. and De Ost, B. and Holt, A. and Lamers, E. and Geussens, Y. and Nuyts, S. and Van den Weyngaert, D. and Van den Wyngaert, T. and Vermorken, J.B. and Gregoire, V. |
| ||Radiation Oncology. 2013; 8(1) |
| ||[Pubmed] |
|5 ||RapidArc, SmartArc and TomoHD compared with classical step and shoot and sliding window intensity modulated radiotherapy in an oropharyngeal cancer treatment plan comparison || |
| ||Dirk Van Gestel,Corine van Vliet-Vroegindeweij,Frank Van den Heuvel,Wouter Crijns,Ann Coelmont,Bie De Ost,Andrea Holt,Emmy Lamers,Yasmyne Geussens,Sandra Nuyts,Danielle Van den Weyngaert,Tim Van den Wyngaert,Jan B Vermorken,Vincent Gregoire |
| ||Radiation Oncology. 2013; 8(1): 37 |
| ||[Pubmed] |
|6 ||Intensity modulated radiation therapy (IMRT) in the treatment of squamous carcinoma of the oropharynx: An overview || |
| || Guha, S., Kelly, C.G., Guha, R., Achari, R., Mallick, I., Paleri, V., Munro, A.J., Chatterjee, S. |
| ||Journal of Cancer Science and Therapy. 2012; 4(4): 77-83 |
| ||[Pubmed] |
|7 ||Functional outcomes after treatment of advanced oropharyngeal carcinoma with radiation or chemoradiation || |
| || Myers, C., Kerr, P., Cooke, A., Bammeke, F., Butler, J., Lambert, P. |
| ||Journal of Otolaryngology - Head and Neck Surgery. 2012; 41(2): 108-118 |
| ||[Pubmed] |
|8 ||Risk factors for osteoradionecrosis after head and neck radiation: a systematic review || |
| ||Syed Nabil, Nabil Samman |
| ||Oral Surgery Oral Medicine Oral Pathology and Oral Radiology. 2012; 113(1): 54 |
| ||[VIEW] |
|9 ||Dosimetric and radiobiological comparison of helical tomotherapy, forward-planned intensity-modulated radiotherapy and two-phase conformal plans for radical radiotherapy treatment of head and neck squamous cell carcinomas || |
| || Chatterjee, S., Willis, N., Locks, S.M., Mott, J.H., Kelly, C.G. |
| ||British Journal of Radiology. 2011; 84(1008): 1083-1090 |
| ||[Pubmed] |
|10 ||Radiation therapy in the early 21 st century: Technological advances || |
| || Enferadi, M., Sadeghi, M., Shirazi, A. |
| ||Current Cancer Therapy Reviews. 2011; 7(4): 303-318 |
| ||[Pubmed] |
|11 ||A Multicentre Timing Study of Intensity-modulated Radiotherapy Planning and Delivery || |
| ||S.J. Thomas,A. Vinall,A. Poynter,D. Routsis |
| ||Clinical Oncology. 2010; 22(8): 658 |
| ||[Pubmed] |
|12 ||New developments in arc radiation therapy: A review || |
| ||David A. Palma,Wilko F.A.R. Verbakel,Karl Otto,Suresh Senan |
| ||Cancer Treatment Reviews. 2010; 36(5): 393 |
| ||[Pubmed] |
|13 || A multicentre timing study of intensity-modulated radiotherapy planning and delivery || |
| ||Thomas, S.J., Vinall, A., Poynter, A., Routsis, D. |
| ||Clinical Oncology. 2010; 22(8): 658-665 |
| ||[Pubmed] |
|14 || New developments in arc radiation therapy: A review || |
| ||Palma, D.A., Verbakel, W.F.A.R., Otto, K., Senan, S. |
| ||Cancer Treatment Reviews. 2010; 36(5): 393-399 |
| ||[Pubmed] |
|15 || Helical tomotherapy for head and neck squamous cell carcinoma: Dosimetric comparison with linear accelerator-based step-and-shoot IMRT || |
| ||Murthy, V., Master, Z., Gupta, T., Ghosh-Laskar, S., Budrukkar, A., Phurailatpam, R., Agarwal, J. |
| ||Journal of Cancer Research and Therapeutics. 2010; 6(2): 194-198 |
| ||[Pubmed] |
|16 ||IMRT and IGRT in head and neck cancer: Have we delivered what we promised? || |
| ||Gupta Tejpal, Agarwal JaiPrakash, Bannerjee Susovan, Sarbani Ghosh-Laskar, Vedang Murthy, Ashwini Budrukkar |
| ||Indian Journal of Surgical Oncology. 2010; 1(2): 166 |
| ||[VIEW] |
| || |